Kimberly-Clark (KMB)
Consumo básico / Higiene y cuidado personal
Global leader in tissue and personal care hygiene products (Huggies, Kleenex, Scott, Kotex, Depend), with #1 or #2 brands in ~70 countries, navigating two simultaneous corporate transactions — the IFP joint venture with Suzano and the pending merger with Kenvue. Valued on a standalone basis (excluding Kenvue, which has not closed) at $110 on a P/E of 20× over normalized earnings, 5-year base value $128 (+8% including the dividend): Fairly valued — a defensive, low-growth compounder at a reasonable price, with the Kenvue outcome as the largest structural variable not incorporated into the base case.
- Price
- $110.49
- Intrinsic value (5y, base)
- $128
- Total annual return (5y)
- 7.7%
- Status (nominal)
- Fairly valued
- Margin of safety
- +13%
The essentials
- Global leader in tissue and personal care hygiene: #1 or #2 market-share brands in ~70 countries (Huggies, Kleenex, Scott, Kotex, Depend), with 74 manufacturing plants in 30 countries. Organic growth is modest but positive (+1.7% in 2025, volume +2.5%), obscured in reported revenue (~-2%/year in FY24-25) by portfolio divestitures and currency effects.
- Underway are two large simultaneous corporate transactions: the IFP joint venture with Suzano (51% for ~US$1.7bn, closing expected mid-2026) and the pending merger with Kenvue (announced Nov-2025, ~46% dilution for current K-C shareholders, deadline Nov-2-2026) — the largest structural variable to watch, deliberately not incorporated into the standalone base case.
- At $110, valued on a standalone basis at a P/E of 20× (lower-middle part of the consumer-staple band [16-22×]) over normalized earnings from continuing operations, 5-year base value $128 (+8% including the dividend, a 54-year dividend aristocrat, yield ~4.7%): Fairly valued.
Intrinsic value — two valuation methods
Total return at 5 years: 7.8%/year = 3.0% appreciation + 4.8% dividend. The target price ($128) is ex-dividend; the $28 in dividends collected over 5 years are added separately.
By both methods, the value today (DCF $138 · Multiples $127) exceeds the market price ($110).
Pillars of the analysis
The verdict — today vs 5 years
Today — fairly valued: at $110 trades ~13.2% below its value discounted to today (~$127); the discount is positive but does not reach the margin of safety we require (≥38%).
At 5 years — En valor: the target price ($128) plus dividends yield between the 4% floor and the 10% average return — a reasonable return, though without the margin of a great investment.
The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$82.
Thesis
The business
Kimberly-Clark is a global consumer-staple in tissue and personal care hygiene, with leading brands (Huggies, Kleenex, Scott, Kotex, Depend) holding the #1 or #2 position in ~70 countries. Organic growth is modest but positive (+1.7% in 2025, volume +2.5%), obscured in reported revenue by portfolio divestitures and currency effects. The company is undergoing two simultaneous corporate transactions — the IFP joint venture with Suzano and the pending merger with Kenvue — that introduce unusual complexity and uncertainty for a mature consumer staple.
The valuation
It is valued on a standalone basis (excluding the effect of the Kenvue merger, which has not yet closed) at a P/E on normalized net income from continuing operations — excluding Transformation Initiative charges, Kenvue transaction costs, and the results of IFP's discontinued operations — which starts at ~US$1.89bn (margin ~11.4%) and compounds toward ~$128 via a multiple of 20× (lower-middle part of the consumer-staple band [16-22×], below peers such as Procter & Gamble/Colgate, given the weaker recent organic momentum and corporate uncertainty).
The margin of safety
It trades close to intrinsic value, far from the required margin of safety. The base-case return combines modest price appreciation with a high dividend yield (~4.7% at today's price, with 54 consecutive years of increases), giving a total +8%: Fairly valued. It is neither a deep bargain nor an overvalued business — it is a defensive, low-growth compounder at a reasonable price, with the outcome of the Kenvue merger as the variable not incorporated into the base case that could move the result in either direction.
What to watch
The central disconfirming test is execution: does volume sustain organic growth against private label while tariffs are absorbed through productivity, or does margin stall? And the largest structural event: the outcome of the Kenvue merger (deadline Nov-2-2026, with shareholder litigation already filed) — a successful close with good execution could add strategic value, but a failed integration or poorly executed dilution would destroy value for current K-C shareholders.
Educational / informational. Does not constitute investment advice.